VEGF-activated miR-144 regulates autophagic survival of prostate cancer cells against Cisplatin

Tumor Biology

Volumn 37, Issue 12, 2016, Pages 15627-15633

  Liu, Feng ^a   Wang, Jihong ^b   Fu, Qiang ^b   Zhang, Xinru ^b   Wang, Ying ^c   Liu, Jialin ^d   Huang, Jianwen ^b   Lv, Xiangguo ^b  

^a Division of Minimally Invasive Gynecology   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^c Urology Institute of Fudan University   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Autophagy; Beclin 1; Cisplatin; miR 144; Prostate cancer; VEGF

Indexed keywords

BECLIN 1; CHOLECYSTOKININ OCTAPEPTIDE; CISPLATIN; MESSENGER RNA; MICRORNA; MICRORNA 144; UNCLASSIFIED DRUG; VASCULOTROPIN;

3' UNTRANSLATED REGION; ADULT; AGED; APOPTOSIS; ARTICLE; AUTOPHAGY; BIOINFORMATICS; CANCER RESISTANCE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIMIT OF QUANTITATION; LUCIFERASE ASSAY; MALE; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN RNA BINDING; TREATMENT OUTCOME; UPREGULATION;

EID: 84946924514     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4383-1     Document Type: Article

References (47)

1. Saylor PJ. Prostate cancer: the androgen receptor remains front and centre. Nat Rev Clin Oncol. 2013;10:126–8.
2. Alva A, Hussain M. The changing natural history of metastatic prostate cancer. Cancer J. 2013;19:19–24.
3. Beltran H, Rubin MA. New strategies in prostate cancer: Translating genomics into the clinic. Clin Cancer Res. 2013;19:517–23.
4. Xin L. Cells of origin for cancer: an updated view from prostate cancer. Oncogene. 2013;32:3655–63.
5. Huang S, Liao Q, Li L, Xin D. Pttg1 inhibits smad3 in prostate cancer cells to promote their proliferation. Tumour Biol. 2014;35:6265–70.
6. Xia Q, Li C, Bian P, Wang J, Dong S. Targeting smad3 for inhibiting prostate cancer metastasis. Tumour Biol. 2014;35:8537–41.
7. Lin R, Feng J, Dong S, Pan R, Zhuang H, Ding Z. Regulation of autophagy of prostate cancer cells by beta-catenin signaling. Cell Physiol Biochem. 2015;35:926–32.
8. Li T, Zhao X, Mo Z, Huang W, Yan H, Ling Z, et al. Formononetin promotes cell cycle arrest via downregulation of akt/cyclin d1/cdk4 in human prostate cancer cells. Cell Physiol Biochem. 2014;34:1351–8.
9. Gillies K, Wertman J, Charette N, Dupre DJ. Anterograde trafficking of cxcr4 and ccr2 receptors in a prostate cancer cell line. Cell Physiol Biochem. 2013;32:74–85.
10. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A. 2011;108:1850–5.
11. Villar J, Quadri HS, Song I, Tomita Y, Tirado OM, Notario V. Pcph/entpd5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase calpha-mediated bcl-2 stabilization. Cancer Res. 2009;69:102–10.
12. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized pt(iv) prodrug-plga-peg nanoparticles. Proc Natl Acad Sci U S A. 2008;105:17356–61.
13. Green DR, Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell. 2014;157:65–75.
14. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27–42.
15. Guo JY, Xia B, White E. Autophagy-mediated tumor promotion. Cell. 2013;155:1216–9.
16. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12:401–10.
17. Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Lu TL, et al. Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer. Sci Rep. 2015;5:14045.
18. Farrow JM, Yang JC, Evans CP. Autophagy as a modulator and target in prostate cancer. Nat Rev Urol. 2014;11:508–16.
19. Shi Y, Han JJ, Tennakoon JB, Mehta FF, Merchant FA, Burns AR, et al. Androgens promote prostate cancer cell growth through induction of autophagy. Mol Endocrinol. 2013;27:280–95.
20. Ouyang DY, Xu LH, He XH, Zhang YT, Zeng LH, Cai JY, et al. Autophagy is differentially induced in prostate cancer lncap, du145 and pc-3 cells via distinct splicing profiles of atg5. Autophagy. 2013;9:20–32.
21. Lian J, Karnak D, Xu L. The bcl-2-beclin 1 interaction in (−)-gossypol-induced autophagy versus apoptosis in prostate cancer cells. Autophagy. 2010;6:1201–3.
22. Lamoureux F, Zoubeidi A. Dual inhibition of autophagy and the akt pathway in prostate cancer. Autophagy. 2013;9:1119–20.
23. Eichmann A, Simons M. Vegf signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol. 2012;24:188–93.
24. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307.
25. Ferrara N, Gerber HP, LeCouter J. The biology of vegf and its receptors. Nat Med. 2003;9:669–76.
26. Xiao X, Prasadan K, Guo P, El-Gohary Y, Fischbach S, Wiersch J, et al. Pancreatic duct cells as a source of vegf in mice. Diabetologia. 2014;57:991–1000.
27. Xiao X, Guo P, Chen Z, El-Gohary Y, Wiersch J, Gaffar I, et al. Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem. 2013;288:8636–46.
28. Bagri A, Kouros-Mehr H, Leong KG, Plowman GD. Use of anti-vegf adjuvant therapy in cancer: Challenges and rationale. Trends Mol Med. 2010;16:122–32.
29. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (vegf) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35–52.
30. Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (vegf) as the mitogen. Mol Med. 1995;1:182–93.
31. Cheng SY, Nagane M, Huang HS, Cavenee WK. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms vegf121 and vegf165 but not vegf189. Proc Natl Acad Sci U S A. 1997;94:12081–7.
32. Huez I, Creancier L, Audigier S, Gensac MC, Prats AC, Prats H. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol. 1998;18:6178–90.
33. Di Leva G, Croce CM. Mirna profiling of cancer. Curr Opin Genet Dev. 2013;23:3–11.
34. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.
35. Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through mir-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105:755–62.
36. Wang F, Xiao W, Sun J, Han D, Zhu Y. Mirna-181c inhibits egfr-signaling-dependent mmp9 activation via suppressing akt phosphorylation in glioblastoma. Tumour Biol. 2014;35:8653–8.
37. Liu G, Jiang C, Li D, Wang R, Wang W. Mirna-34a inhibits egfr-signaling-dependent mmp7 activation in gastric cancer. Tumour Biol. 2014;35:9801–6.
38. Zhao M, Huang J, Gui K, Xiong M, Cai G, Xu J, et al. The downregulation of mir-144 is associated with the growth and invasion of osteosarcoma cells through the regulation of tagln expression. Int J Mol Med. 2014;34:1565–72.
39. Cao T, Li H, Hu Y, Ma D, Cai X. Mir-144 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting e2f3. Tumour Biol. 2014;35:10759–64.
40. Zha W, Cao L, Shen Y, Huang M. Roles of mir-144-zfx pathway in growth regulation of non-small-cell lung cancer. PLoS One. 2013;8, e74175.
41. Hassan F, Nuovo GJ, Crawford M, Boyaka PN, Kirkby S, Nana-Sinkam SP, et al. Mir-101 and mir-144 regulate the expression of the cftr chloride channel in the lung. PLoS One. 2012;7, e50837.
42. Iwaya T, Yokobori T, Nishida N, Kogo R, Sudo T, Tanaka F, et al. Downregulation of mir-144 is associated with colorectal cancer progression via activation of mtor signaling pathway. Carcinogenesis. 2012;33:2391–7.
43. Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, et al. Clinical significance of mir-144-zfx axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br J Cancer. 2012;107:1345–53.
44. Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, Sileri P, Cretella M, Pallone F, et al. Differential expression of mir-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol. 2011;46:1391–402.
45. Huang SQ, Liao QJ, Wang XW, Xin DQ, Chen SX, Wu QJ, et al. Rnai-mediated knockdown of pituitary tumor- transforming gene-1 (pttg1) suppresses the proliferation and invasive potential of pc3 human prostate cancer cells. Braz J Med Biol Res. 2012;45:995–1001.
46. Horoszewicz JS, Leong SS, Carter WA. Differential susceptibility of spleen focus-forming virus and murine leukemia viruses to ansamycin antibiotics. Antimicrob Agents Chemother. 1977;12:4–10.
47. Coronnello C, Benos PV. Comir: Combinatorial microRNA target prediction tool. Nucleic Acids Res. 2013;41:W159–64.